Uncategorized
how many units is 5mg of tirzepatide
How Many Units Is 5mg of Tirzepatide? A Researcher’s Reconstitution Guide
If you’re working with compounded tirzepatide in a research setting, the most common question you’ll run into is: how many units is 5mg of tirzepatide?
The short answer: it depends entirely on your reconstitution concentration. There is no single fixed unit value — the number of units you draw on a U-100 insulin syringe changes based on how much bacteriostatic water you added to your vial.
This guide walks through the calculation clearly, with a full reference table covering the most common vial sizes and concentrations used in research.
Why Units and Milligrams Are Not the Same Thing
This is where most errors happen. On a standard U-100 insulin syringe, the markings go from 0 to 100 units — and those 100 units equal exactly 1mL of liquid. Every single unit on the syringe represents 0.01mL of volume.
Units measure volume drawn, not drug amount. How much tirzepatide that volume contains depends entirely on the concentration of your reconstituted solution.
The universal formula:
Units = (Dose in mg ÷ Concentration in mg/mL) × 100So for 5mg:
- At 10 mg/mL → (5 ÷ 10) × 100 = 50 units
- At 5 mg/mL → (5 ÷ 5) × 100 = 100 units
- At 20 mg/mL → (5 ÷ 20) × 100 = 25 units
Same dose. Completely different syringe readings. This is why concentration must be confirmed before every draw.
Reference Table: How Many Units Is 5mg of Tirzepatide?
| Vial Size | BAC Water Added | Concentration | 5mg Dose = Units |
|---|---|---|---|
| 10mg vial | 1 mL | 10 mg/mL | 50 units |
| 10mg vial | 2 mL | 5 mg/mL | 100 units |
| 15mg vial | 1 mL | 15 mg/mL | 33 units |
| 30mg vial | 3 mL | 10 mg/mL | 50 units |
| 30mg vial | 6 mL | 5 mg/mL | 100 units |
| Any vial | Custom | 20 mg/mL | 25 units |
The most common research setup — a 10mg vial reconstituted with 2mL bacteriostatic water — gives a 5 mg/mL concentration, meaning 5mg = 100 units. At a 10 mg/mL concentration (2mL BAC water into a 20mg vial), 5mg = 50 units.
How to Reconstitute Tirzepatide Correctly
Getting the concentration right starts with proper reconstitution. Here is the standard laboratory protocol:
- Remove the caps from both the tirzepatide vial and the bacteriostatic water vial. Wipe both stoppers with an alcohol swab and allow to air dry.
- Draw your BAC water into a syringe — use the volume that gives you your target concentration per the table above.
- Inject slowly along the inner wall of the tirzepatide vial. Do not inject directly onto the powder.
- Swirl gently — do not shake. Tirzepatide may take several minutes to fully dissolve. The final solution should be clear and colourless.
- Label the vial with the reconstitution date and concentration (e.g. 5 mg/mL, reconstituted 25 May 2026).
- Store at 2–8°C (refrigerated). Do not freeze reconstituted peptide. Most preparations with bacteriostatic water are stable for 28 days refrigerated.
For a broader overview of reconstitution principles that apply across all research peptides, see our guide: How to Reconstitute Research Peptides — Penguin Peptide Lab (internal link — publish this guide next).
Common Mistakes to Avoid
Switching concentrations mid-protocol without recalculating If you receive a new vial from a different batch or source with a different stated concentration, your unit draw changes completely. A researcher drawing 50 units at 10 mg/mL and then switching to a 20 mg/mL vial without recalculating will accidentally administer double the intended dose.
Shaking the vial Tirzepatide is a fragile peptide. Shaking rather than gently swirling can degrade the compound and reduce potency.
Using sterile water instead of bacteriostatic water Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits bacterial growth across multiple draws from the same vial. Sterile water has no preservative — multi-draw vials reconstituted with sterile water can become contaminated within hours.
Reading the wrong end of the syringe Always read from the bottom of the plunger stopper (the flat edge closest to the needle), not the top dome. A one-unit misread at high concentrations can represent a meaningful dosing error.
Tirzepatide in the Research Context
Tirzepatide (LY3298176) is a dual GIP/GLP-1 receptor agonist originally developed by Eli Lilly and studied extensively in clinical trials for type 2 diabetes and metabolic research. Its dual-agonist mechanism differentiates it from single GLP-1 receptor agonists like semaglutide — and has made it a subject of significant interest in metabolic, adipose tissue, and longevity research models.
For context on how tirzepatide compares mechanistically with other GLP-1/GIP class compounds, the SURPASS clinical trial programme on ClinicalTrials.gov provides detailed phase 3 data across multiple dosing arms including 5mg, 10mg, and 15mg weekly administration.
For a deeper look at how tirzepatide fits within the broader peptide research landscape alongside compounds like BPC-157 and TB-500, see our post: What Are Peptides? A Researcher’s Introduction (internal).
Quick Reference: The 5mg Unit Answer
| Concentration | Units for 5mg |
|---|---|
| 5 mg/mL | 100 units |
| 10 mg/mL | 50 units |
| 20 mg/mL | 25 units |
Always confirm concentration from your vial label before drawing. When in doubt, apply the formula: (dose ÷ concentration) × 100.
Research Notice
All information in this post is provided for educational and research purposes only. Tirzepatide supplied by Penguin Peptide Lab is intended strictly for laboratory and in-vitro research use. It is not a medicine, has not been evaluated or approved by the FDA for general use, and is not intended for human consumption or therapeutic application. Researchers should consult applicable institutional guidelines and regulatory frameworks before beginning any study.
